Protagonist Therapeutics
Protagonist Therapeutics
PTGX
NASDAQ
42.89
USD
17.15%
About
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases.
Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs.
Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 509.7K |
| Three Month Average Volume | 20.5M |
| High Low | |
| Fifty-Two Week High | 43.76 USD |
| Fifty-Two Week Low | 13.72 USD |
| Fifty-Two Week High Date | 29 Aug 2024 |
| Fifty-Two Week Low Date | 25 Oct 2023 |
| Price and Volume | |
| Current Price | 42.89 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 8.67% |
| Thirteen Week Relative Price Change | 42.36% |
| Twenty-Six Week Relative Price Change | 21.33% |
| Fifty-Two Week Relative Price Change | 72.69% |
| Year-to-Date Relative Price Change | 57.95% |
| Price Change | |
| One Day Price Change | 1.42% |
| Thirteen Week Price Change | 52.36% |
| Twenty-Six Week Price Change | 33.41% |
| Five Day Price Change | 2.90% |
| Fifty-Two Week Price Change | 116.40% |
| Year-to-Date Price Change | 87.05% |
| Month-to-Date Price Change | 14.56% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 5.83409 USD |
| Book Value Per Share (Most Recent Quarter) | 9.21213 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 5.83409 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 9.21213 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 2.50637 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.05702 USD |
| Revenue Per Share (Trailing Twelve Months) | 5.22056 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.39095 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 2.63701 USD |
| Normalized (Last Fiscal Year) | -1.39095 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.39095 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 2.78379 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.39095 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 2.63701 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.91969 USD |
| Cash Per Share (Most Recent Quarter) | 9.59798 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.37373 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 2.79617 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 3.77651 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -283 |
| Cash Flow Revenue (Trailing Twelve Months) | 72 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 54.09% |
| Pretax Margin (Last Fiscal Year) | -131.59% |
| Pretax Margin (5 Year) | -332.38% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -156.09% |
| Operating Margin (Trailing Twelve Months) | 47.71% |
| Operating Margin (5 Year) | -347.69% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -131.59% |
| Net Profit Margin (Trailing Twelve Months) | 53.26% |
| Net Profit Margin (5 Year) | -332.81% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 3.75% |
| Tangible Book Value (5 Year) | 24.51% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | 14.17% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -5.23% |
| Revenue Growth (5 Year) | 27.97% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 4.62% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 26.28% |
| EPS Change (Trailing Twelve Months) | 198.60% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 8 |
| Price to Tangible Book (Most Recent Quarter) | 5 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 11 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -563,997,000 |
| Net Debt (Last Fiscal Year) | -341,617,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 42 |
| Price to Sales (Trailing Twelve Months) | 8 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 16 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 12 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 13 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 12 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 16 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 7 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 12 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 17 |
| Current Ratio (Most Recent Quarter) | 14 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -70,845,000 |
| Free Cash Flow (Trailing Twelve Months) | 230.8M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -26.06% |
| Return on Assets (Trailing Twelve Months) | 36.35% |
| Return on Assets (5 Year) | -35.90% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -28.59% |
| Return on Equity (Trailing Twelve Months) | 40.69% |
| Return on Equity (5 Year) | -43.21% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -28.53% |
| Return on Investment (Trailing Twelve Months) | 39.20% |
| Return on Investment (5 Year) | -41.36% |